Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Link opens in a new tab
Search content at UTMB Health Research Expert Profiles
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Effects of thiazolidinedione in patients with active bladder cancer
Roger Li
, Michael J. Metcalfe
, James E. Ferguson
, Sharada Mokkapati
, Graciela M. Nogueras González
, Colin P. Dinney
, Neema Navai
, David J. McConkey
,
Sunil K. Sahai
, Ashish M. Kamat
Research output
:
Contribution to journal
›
Article
›
peer-review
5
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Effects of thiazolidinedione in patients with active bladder cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Thiazolidinediones
100%
Bladder Cancer
100%
Radical Cystectomy
66%
Cancer-specific Survival
50%
Overall Survival
33%
Recurrence-free Survival
33%
Pioglitazone
25%
Patients with Diabetes Mellitus
16%
Urothelial Carcinoma
16%
Survival Rate
8%
Cancer Outcomes
8%
Multivariate Analysis
8%
Adjuvant Chemotherapy
8%
Significant Predictors
8%
Subgroup Analysis
8%
Confidence Interval
8%
Hazard Ratio
8%
Retrospective Cohort
8%
T Staging
8%
Non-muscle Invasive Bladder Cancer (NMIBC)
8%
Muscle-invasive Bladder Cancer
8%
Bladder-sparing
8%
Medicine and Dentistry
Bladder Cancer
100%
Thiazolidinedione
100%
Cystectomy
66%
Cancer Specific Survival
50%
Overall Survival
33%
Recurrence Free Survival
33%
Pioglitazone
25%
Diabetes Mellitus
16%
Transitional Cell Carcinoma
16%
Patient with Diabetes
16%
Malignant Neoplasm
8%
Bladder
8%
Survival Rate
8%
Adjuvant Chemotherapy
8%
Hazard Ratio
8%
Subgroup Analysis
8%
Bladder Muscle
8%
Non Muscle Invasive Bladder Cancer
8%
Muscle Invasive Bladder Cancer
8%
Multivariate Analysis
8%
Nursing and Health Professions
Bladder Cancer
100%
Thiazolidinedione
100%
Cystectomy
66%
Cancer Specific Survival
50%
Overall Survival
33%
Recurrence Free Survival
33%
Pioglitazone
25%
Diabetes Mellitus
16%
Patient with Diabetes
16%
Transitional Cell Carcinoma
16%
Malignant Neoplasm
8%
Adjuvant Chemotherapy
8%
Survival Rate
8%
Confidence Interval
8%
Hazard Ratio
8%
Perioperative
8%
Muscle Invasive Bladder Cancer
8%
Non Muscle Invasive Bladder Cancer
8%
Multivariate Analysis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Thiazolidinedione
100%
Bladder Cancer
100%
Cancer Specific Survival
50%
Overall Survival
33%
Recurrence Free Survival
33%
Pioglitazone
25%
Diabetes Mellitus
16%
Transitional Cell Carcinoma
16%
Malignant Neoplasm
8%
Chemotherapy
8%
Survival Rate
8%
Muscle Invasive Bladder Cancer
8%
Non Muscle Invasive Bladder Cancer
8%
Biochemistry, Genetics and Molecular Biology
Thiazolidinedione
100%
Cancer Specific Survival
50%
Overall Survival
33%
Recurrence Free Survival
33%
Pioglitazone
25%
Survival Rate
8%
Multivariate Analysis
8%